Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Five9 has entered into a definitive agreement to acquire Level AI, an AI-native customer experience platform, for $325 million in cash. The acquisition aims to enhance Five9's AI capabilities for agent performance and automated customer interactions, while providing a standalone AI solution for enterprises not yet ready to migrate their contact centers to the cloud.
Value
$325M
Counterparty
Ujwal, Inc. (d/b/a Level AI)
“Our vision for the future of CX is one where AI and human agents work as a coordinated system, each making the other better. Level AI will advance this vision by expanding our AI capabilities, adding experienced AI-native builders to our team, and delivering additional AI solutions for research, analysis, and planning so human agents can focus on high-value and complex customer interactions.”
Amit Mathradas, Chief Executive Officer at Five9
“We built Level AI so every customer conversation makes the next one better, for customers and for the people who serve them. Five9 shares that focus.”
Ashish Nagar, Founder and Chief Executive Officer of Level AI
Willdan Group Signs $285M M&A Deal with Mantis Intermediate Holdings, LLC
Willdan Group completed its acquisition of Mantis Innovation for approximately $285 million in cash. The transaction was funded through $250 million in new term loan borrowings and $35 million from an existing revolving credit facility.
Flex Ltd. shareholders approved the separation of the company's cloud and power infrastructure business through a distribution of Axiom Solutions International, Inc. common stock. The transaction involves a court-approved capital reduction to effect a distribution in specie of approximately 88.0% to 94.0% of Axiom Solutions shares to Flex shareholders on a pro rata basis.
Armada Acquisition Corp. III M&A Deal with Brains Bioceutical Corp.
Armada Acquisition Corp. III (SPAC) entered into a definitive business combination agreement with Brains Bioceutical Corp., a life sciences company specializing in pharmaceutical API manufacturing and drug development. The transaction values Brains at an implied pre-money equity value of $750 million and will result in the combined company, Brains Therapeutics Corp., listing on the Nasdaq under the ticker symbol 'BAPI'.
Eton Pharmaceuticals announced preliminary results from a pilot study of ET-700 for Wilson disease, demonstrating significantly improved gastrointestinal tolerability compared to GALZIN. While ET-700 showed a lower rate of adverse events (8% vs 67% for GALZIN), its copper absorption inhibition was more modest (12% reduction vs 46% for GALZIN), leading the company to plan additional study arms in 2027 for faster-release formulations.
“The tolerability findings are exciting and reinforce our belief that a slower release zinc can improve tolerability, which is a notorious issue with zinc treatment. We are encouraged by the initial results, which showed a benefit over placebo, and our next objective is to improve ET-700’s effect on copper absorption.”
Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals
BRC Group Holdings Divestiture to Oaktree Capital Management, L.P. for $62.2M
BRC Group Holdings completed the sale of its remaining membership interests in Great American Holdings, LLC to affiliates of Oaktree Capital Management for $62.25 million in cash. The company used approximately $51.7 million of the proceeds to repay outstanding term-loan indebtedness owed to Oaktree-affiliated lenders.
PMGC Holdings announced results from a preclinical study of its engineered probiotic candidate EL-32, both as a standalone and in combination with semaglutide. The study identified a statistically significant greater absolute lean mass at the highest EL-32 dose compared to semaglutide alone, supporting the company's muscle-preservation thesis. While the combination improved insulin sensitivity and reduced body weight, it did not demonstrate a consistent additive metabolic benefit over semaglutide alone across all measures.
Honda Auto Receivables 2026-4 Owner Trust Capital Raise of $2.11B
Honda Auto Receivables 2026-4 Owner Trust filed a prospectus for the issuance of $2.1 billion in aggregate principal amount of Asset Backed Notes across five classes (A-1, A-2a, A-2b, A-3, and A-4). American Honda Finance Corporation will retain at least 5% of each class of the notes as part of the securitization structure.
Macquarie Energy Transition Infrastructure Fund Capital Raise of $4.12M
Macquarie Energy Transition Infrastructure Fund, L.P. sold unregistered limited partnership units for aggregate consideration of approximately $4.125 million on October 1, 2026. The sale was part of a continuous private offering that has raised approximately $715.3 million across the broader METI Program since July 2025.
Honda Auto Receivables 2026-4 Owner Trust Capital Raise of $2.11B
Honda Auto Receivables 2026-4 Owner Trust entered into an underwriting agreement for the sale of $2.1 billion in asset-backed notes across five classes (Class A-1 through A-4). The notes are backed by retail installment sale contracts for Honda and Acura automobiles and are expected to be issued on November 12, 2026.
Core University Living Real Estate Income Trust Capital Raise of $11M
Core University Living Real Estate Income Trust conducted several private placements and distribution reinvestment plan sales to accredited investors between September and November 2026. The company raised approximately $10.97 million in total across various share classes, including Class A, E, F-S, and F-I shares. These unregistered sales were conducted under Section 4(a)(2) and Rule 506 of Regulation D.
Franklin BSP Real Estate Debt Capital Raise of $7.21M
Franklin BSP Real Estate Debt, Inc. sold 291,392.59 shares of its Class G, Class G-S, and Class I common stock in a continuous private offering for aggregate consideration of approximately $7.2 million. The shares were sold at prices ranging from $24.54 to $24.71 per share under a Regulation D exemption from registration.
King Resources Global Signs $22.3M M&A Deal with Herbertini Limited
King Resources Global, Inc., through its subsidiary Heavenly Grace, entered into three separate purchase agreements to acquire a total of 29 collectible items for an aggregate consideration of approximately $22.26 million. The company will settle the acquisitions by issuing common stock at a fixed price of $0.236 per share to the three Hong Kong-based sellers.
Value
$22.3M
Counterparty
Herbertini Limited, Silver Bloom Properties Limited, and Grand View Assets Limited
Campbell Fund Trust sold approximately $5.77 million in Units of Beneficial Interest to existing and new unitholders on October 31, 2026. The private placement included $3.83M for Series A, $1.72M for Series D, and $0.23M for Series W units. The securities were issued in reliance on Section 4(2) and Regulation D exemptions from registration.
Hyundai Auto Receivables Trust 2026-D Capital Raise
Hyundai Auto Receivables Trust 2026-D is filing legal and tax opinions in connection with the issuance of asset-backed notes. The notes are described in a prospectus dated November 3, 2026, representing a securitization of auto receivables sponsored by Hyundai Capital America.
Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.
Curaleaf Holdings issued a statement reaffirming its outstanding premium bid to acquire all common shares of Aurora Cannabis, despite Aurora announcing an alternative transaction with Organigram Global Inc. Curaleaf argues its offer provides superior value and synergies compared to the Organigram proposal and criticized the Aurora board for refusing to engage directly or grant due diligence access.
Hyundai Auto Receivables Trust 2026-D Capital Raise of $2B
Hyundai Auto Receivables Trust 2026-D entered into an underwriting agreement to sell $1,997,210,000 in asset-backed notes to a group of underwriters led by BNP Paribas Securities Corp. The notes, which include Class A, Class B, and Class C tranches, are backed by retail installment sale contracts for automobiles and are expected to be issued on November 10, 2026.
Sports Entertainment Gaming Global Nasdaq/NYSE Compliance Notice
Sports Entertainment Gaming Global Corporation has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its delinquent Quarterly Report on Form 10-Q for the period ended June 30, 2026. As a result, the previously scheduled hearing before the Nasdaq Hearings Panel has been cancelled, and the company's common stock will continue to be listed and traded on The Nasdaq Global Market.
Rockwell Automation delivered a strong fiscal 2026 with 9% core growth and 22.2% margins, guiding to 6-9% organic growth for fiscal 2027 despite persistent inflationary pressures and project timing delays in mining.
Enhanced Group Signs $15M M&A Deal with DEAG Deutsche Entertainment AG
Enhanced Group Inc. has entered into definitive exchange agreements to acquire an approximately 77% controlling interest in DEAG Deutsche Entertainment AG, a Berlin-headquartered live entertainment and ticketing platform. The all-stock transaction involves the issuance of approximately 11 million shares of Class A common stock at a value of $8 per share, complemented by a concurrent $15 million PIPE investment to fund growth and operations.
Value
$15M
Counterparty
DEAG Deutsche Entertainment AG
“I believe one of the most significant long-term consequences of AI and robotics will be a gradual reduction in the need for human labor. And I believe people will mostly allocate this free time to shared, real live human experiences. This creates scarcity, as sports and live experiences cannot be automated or replicated by AI. A live game, a concert, a record broken in front of a crowd - all those moments create goosebumps and become more valuable as everything else becomes digitally abundant. We believe the winners will be the companies that own the content, the stage and the ticket. With DEAG, Enhanced will have all three: owned sports and live IP, a broad promoter and venue network, and proprietary ticketing. And we believe we are acquiring it at a very attractive valuation.”
Maximilian Martin, Co-Founder and Chief Executive Officer of Enhanced
MetaVia announced positive interim data from Part 3B of its Phase 1 trial for DA-1726, showing a statistically significant 68% placebo-adjusted reduction in liver fat and 13.5% weight loss after 16 weeks. The results support the company's plan to initiate a Phase 2 study in patients with MetALD and ALD in the second half of 2027.
“These are the most compelling clinical data we have generated to date supporting DA-1726’s potential as a liver-focused cardiometabolic therapy. A 68% placebo-adjusted reduction in liver fat after approximately 16 weeks, together with all five participants who entered the study with liver steatosis achieving MRI-PDFF below 5%, provides a strong clinical rationale for expanding DA-1726 into liver disease.”
Hyung Heon Kim, President and Chief Executive Officer
“The next step for DA-1726 is clear. We intend to build on these results by advancing the program into both metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD), where there are currently no approved therapies specifically for these patient populations.”
Hyung Heon Kim, President and Chief Executive Officer
Kartoon Studios announced that its subsidiary-sponsored SPAC, Kartoon Studios Acquisition Corp. (KSAC), has filed a registration statement for a proposed $300 million initial public offering. KSAC intends to list on the NYSE and will target business combinations in the media and entertainment sectors, managed by Kartoon Studios' senior leadership team.
Dropbox Signs $350M M&A Deal with Tigris Data Inc.
Dropbox has entered into a definitive agreement to acquire Tigris Data Inc., a globally distributed object storage platform for AI workloads, for approximately $350 million in cash. The acquisition is intended to accelerate Dropbox's expansion into AI infrastructure and supports the launch of DBX Agent Cloud, a new storage and data infrastructure offering for developers.
Myriad Genetics detected unauthorized access to its IT network on November 2, 2026, leading to a temporary suspension of testing operations and order management systems. The company has engaged external experts to investigate the scope of the breach, including potential access to patient records, though most systems have since returned to normal operations. Management currently believes the incident will not have a material adverse effect on the business.
Vivos Inc. completed a Regulation A+ offering of 12,500,000 shares of common stock for gross proceeds of $1.0 million. Additionally, the company issued warrants to purchase 25,000,000 shares to accredited investors for $25,000 and completed a warrant exchange for 8,000,000 shares of common stock.
Remora Capital Corporation issued 201,641.027 shares of common stock at $9.75 per share to investors. The private placement resulted in aggregate proceeds of approximately $1.97 million and was conducted as an unregistered sale exempt from SEC registration.
NextTrip announced the broader U.S. rollout of JOURNYGO, a content-to-commerce platform that connects JOURNY TV viewers with curated travel itineraries via on-screen QR codes. The expansion follows a beta phase that showed high engagement levels, with the platform now featuring approximately 60 content pieces across distribution platforms like Samsung TV Plus and Plex.
“JOURNYGO gives viewers a practical way to act on what inspires them. They can watch a destination come to life on JOURNY TV, scan a QR code and explore a curated itinerary tied to that content.”
Local Bounti Corporation received a nine-month extension from the NYSE to regain compliance with the minimum market capitalization and stockholders' equity standards. The company now has until August 5, 2027, to achieve a 30-day average market capitalization or stockholders' equity of at least $50 million.
Aptevo Therapeutics announced a clinical milestone for mipletamig in frontline AML, achieving a substantial reduction in infusion-related reactions (IRRs) through a refined priming-dose regimen. This optimization, identified through FDA discussions, improves patient tolerability in the ongoing RAINIER study as the company prepares for Phase 2 development.
“We have made substantial progress in improving mipletamig’s tolerability for patients with frontline AML. Mipletamig has demonstrated a differentiated safety and tolerability profile, and successive refinements to the priming-dose regimen have substantially reduced the occurrence of infusion-related reactions. Reducing these reactions matters to patients: it has the potential to make treatment easier to tolerate and limit complications that can disrupt care. These findings are an important part of our preparations for the next stage of clinical development.”
Dirk Huebner, M.D., Chief Medical Officer of Aptevo Therapeutics